Clara Technologies Corp.

Calliditas reported Q2 2024 net revenues of SEK 559.8 million, up from SEK 269.4 million in Q2 2023. TARPEYO net product sales were SEK 493.4 million ($46.3 million), representing 90% growth year over year. Partnership revenue was SEK 66.4 million versus SEK 10.1 million a year ago. Total operating expenses were SEK 537.8 million, and reported operating loss was SEK 31.5 million versus SEK 75.2 million in the prior-year quarter. Excluding Asahi Kasei offer costs and incentive-related provisions, adjusted operating profit was SEK 70.2 million. Cash flow used in operating activities was SEK 7 million, ending cash was SEK 797.3 million, and management said the quarter was almost cash-neutral with cash burn of about $700,000/SEK 7 million. For 2024, management raised full-year Nefecon franchise revenue guidance to $165 million-$185 million.

Renée Aguiar-Lucander emphasized that Q2 was strong both commercially and strategically, calling out record TARPEYO revenue, improved market access after full approval, and operating profitability achieved earlier than planned. She also highlighted major pipeline and partnership milestones, including positive setanaxib data in PBC, the China launch, and the European approval of Kinpeygo. Her tone was upbeat and confident, with repeated references to strong demand, reduced access friction, and continued growth for the rest of the year.

Fredrik Johansson walked through the quarter’s financials, noting SEK 559.8 million of revenue, SEK 537.8 million of operating expenses, and a SEK 31.5 million operating loss. He broke out the SEK 101.7 million of Asahi Kasei-related and incentive-provision costs across R&D, sales and marketing, and G&A, while also pointing to higher R&D spend from Nefecon manufacturing scale-up and higher sales and marketing costs tied to TARPEYO’s U.S. launch momentum. He said operating cash use was only SEK 7 million and that cash ended at SEK 797.3 million, which he described as a healthy cash position.

There was no Q&A session on the call, so no analyst questions were taken. Management instead used the prepared remarks to address the key themes investors would likely focus on: the Asahi Kasei offer, strong TARPEYO demand, payer policy changes, the PBC readout, and the European approval of Kinpeygo. The most notable clarification was that operating profitability was achieved before deal-related costs, and that Q3 will include a EUR 10 million milestone from the European approval.